---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-101017"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2022-04-11T23:59:59+00:00"
generated_at: "2026-06-26T08:09:14.239262+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FDA partial clinical hold on Curis' TakeAim Lymphoma study; no new enrollment

## Summary
- FDA placed partial clinical hold on Phase 1/2 TakeAim Lymphoma study of emavusertib in B-cell malignancies.
- No new patients can be enrolled; current participants benefiting may continue at 300mg BID or lower after reconsent.
- Hold follows prior partial hold on TakeAim Leukemia study announced April 4, 2022; company had already paused enrollment voluntarily.
- FDA requests additional safety, efficacy, and rhabdomyolysis data; company to provide updated guidance after holds resolved.

## SEC filing metadata
- accession: 0001193125-22-101017
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2022-04-11T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000119312522101017/0001193125-22-101017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000119312522101017/d352125d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-101017
- JSON: https://secwatch.observer/filing/0001193125-22-101017.json
- Plain text: https://secwatch.observer/filing/0001193125-22-101017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.